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DNA aberrations in urinary bladder cancer detected 
by flow cytometry and FISH 
Abstract  Detection of molecular alterations i  of poten- 
tial significance for diagnosis and prognosis in bladder can- 
cer. Fluorescence in situ hybridization (FISH) allows vis- 
ualization and quantitation of genes and chromosomes on 
a cell by cell level and can easily be applied to urinary cells. 
To evaluate the sensitivity of FISH for detection of DNA 
aberrations in bladder cancer, formalin-fixed tissues of 293 
tumors were examined by FISH and flow cytometry 
(FCM). Centromere probes for the chromosomes X, Y, 1, 
7, 9, and 17 were used for FISH analysis. FISH was more 
sensitive for detection of quantitative DNA aberrations 
than FCM. An aberration of at least one chromosome was 
found in 107 of 108 tumors (99%), which were tetraploid, 
aneuploid, or multiploid, and in 29 of 49 tumors (59%), 
which were diploid, by FCM. The frequency of FISH ab- 
errations howed greater differences between pTa (47%) 
and pT 1 tumors (85 %; P < 0.0001) than between stages pT 1 
and pT2-4 (98%). The marked genetic difference between 
pTa and pT1 tumors argues against he concept of group- 
ing pTa and pTl  tumors together as "superficial bladder 
cancer." The frequency of tumors with chromosomal b- 
errations detected by FISH increased with the number of 
chromosomes examined. Aneusomy was seen in 68% of 
grade 1 tumors examined for >4 chromosomes, suggesting 
that the cytological diagnosis of bladder cancer ecurrences 
could be substantially improved by FISH. 
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Introduction 
Quantitative aberrations of the cellular DNA content oc- 
cur frequently in bladder cancer [23]. Despite evidence for 
a diagnostic significance ofDNA aneuploidy [5, 6, 24, 26], 
DNA measurement has not become a routine examination 
in bladder cancer patients. This is probably due to the need 
for expensive quipment and specially trained personel to 
perform either flow cytometry (FCM) or DNA image cy- 
tometry. 
Fluorescence in situ hybridization (FISH) is an alter- 
native method for detection of a disturbed cellular DNA 
content. FISH allows visualization and therefore quanti- 
tation of chromosomes and genes on a cell by cell basis 
[9, 10]. FISH is technically easy and there is no need for 
specialized equipment. A major advantage of FISH as 
compared to total DNA measurement by FCM or image 
analysis is the capability to specifically examine chromo- 
somes of interest for numerical aberrations. Since gains of 
chromosomes (polysomy) are frequently the result of 
a generalized alteration of the cellular DNA content in- 
volving most if not all chromosomes (tetraploidization), 
quantitation of a few chromosomes might be sufficient o 
detect DNA aneuploidy by FISH. Several studies have 
suggested that the sensitivity ofFISH for detection of quan- 
titative DNA aberrations exceeds the sensitivity of FCM 
[8, 9]. 
The aim of this study was to compare the sensitivity of 
FISH and FCM for detection of a disturbed DNA content 
in bladder cancer cells. In addition, the relationship be- 
tween DNA aberrations and tumor grade and stage was 
examined, 
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Materials and methods 
Biopsy material 
Formalin-fixed paraffin-embedded tissue samples of primary transi- 
tional cell carcinomas of the urinary bladder were available from the 
archives of the Institute for Pathology, University of Basel, Switzer- 
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land. A total of 293 tumors were selected for this study including 
122 tumors that were previously examined by FISH for multiple chro- 
mosomal aberrations [18, 19, 21]. Tumor stage and grade were de- 
fined according to UICC [25] and WHO [14], using grades 1-3. 
Pure papillomas (grade 0) were excluded. Because of the limitations 
of transurethral biopsies in accurately determining the depth of in- 
vasion of higher stage bladder cancer, all tumors showing muscle in- 
vasion were categorized into one group (pT2-4). Ninety-six tumors 
were confined to the bladder mucosa (pTa), 67 showed minimal in- 
vasion limited to the lamina propria (pT 1), and 130 were muscle-in- 
vasive (pT2-T4). Forty-five tumors were grade 1,109 were grade 2, 
and 139 were grade 3. Fifty-micrometer sections were taken from all 
tissue blocks. Nuclei were enzymatically dissociated as previously 
described [19]. 
Flow cytometry 
FCM for DNA measurement was performed in 237 cases. Nuclei 
were stained with propidium iodide. Dissociated nuclei were ana- 
lyzed with a FACScan flow cytometer (Becton-Dickinson Immuno- 
cytometry System, San Jose, CA). For each specimen 10 000-20 000 
events were collected. The Multicycle Program (Phoenix Flow 
Systems, San Diego, CA) was used for data analysis. The lowest 
G0/G1 peak was considered iploid and given a DNA index (DI) of 
1.00. The DI of other G0/G 1 peaks was calculated as the ratio of their 
G0/G1 peak channel number of the diploid G0/G1 peak channel num- 
ber of the histogram. Tumors with a nondiploid G0/G1 peak with a 
DI_< 1.2 were considered peridiploid. Tumors were defined as dip- 
loid if only one G0/G1 peak was present and the G2M peak was less 
than 15 %. A tumor was categorized as tetraploid if the DI was 1.9-2.1 
or if the G2/M peak of an otherwise diploid tumor was higher than 
or equal to 15%. Tumors with G0/G1 peaks not in the peridiploid 
(DI_< 1.2) or tetraploid (DI 1.9-2.1) range were considered aneu- 
ploid. Multiploid tumors were defined as having more than one non- 
diploid G0/G1 peak. The coefficient of variation (CV) was calculat- 
ed for each G0/G1 peak. Only tumors with a diploid CV < 8% were 
included in this study. 
Scoring of FISH signals 
Interpretation of centromere signals was as described [21, 22]. In 
brief, only cells with at least one bright signal for one of the applied 
probes were scored to avoid false chromosomal losses due to insuf- 
ficient hybridization efficiency. Slides were only scored if at least 
two-thirds of cells were interpretable. Small lymphocytes and gran- 
ulocytes were disregarded. At least 100 nuclei were analyzed. Tu- 
mors were stratified according to fraction of polysomic ells (cells 
with > two centromere signals) and according to their predominant 
population [19, 22]. A tumor was defined as polysomic for a chro- 
mosome if the fraction of polysomic ells was >_10%. A loss of the 
Y chromosome was defined as the presence of _>20% of nullisomic 
cells. The predominant population of a tumor was defined as the larg- 
est abnormal (aneusomic) population having >20% of total cells [20]. 
A loss of chromosome 9 was defined if a tumor was either mono- 
somic for chromosome 9 (_>20% monosomic ells) or its chromo- 
some 9 copy number category (predominant population) was below 
the copy number category for all other chromosomes xamined (ex- 
cept chromosome Y). 
Fluorescence in situ hybridization 
FISH was performed as previously described [19, 21, 22]. The fol- 
lowing centromere probes were used: pY (chr. Y), pBAMX (chr. X), 
pUC177 (chr. 1), p7alphaTET (chr. 7), pHUR98 (chr. 9), and p17H8 
(chr. 17). All probes were generou sly supplied by the UCSF Resource 
for Molecular genetics (Dr. Joe W. Gray, Director). Probe labeling 
was performed with biotin-14-dATP or digoxigenin-ll-dUTP by 
nick translation using standard protocols. For all hybridizations a du- 
al-labeling procedure using centromere probes together with other 
centromeric or locus-specific cosmid probes was used as described 
[18-22]. Cells on slides were denatured in 70% formamide/2X SSC 
(1X SSC is 0.15 M NaC1, 0.015 M Na citrate), pH 7, at 75 °C for 
2.5 rain. Pretreatment of slides was with proteinase K (2.0 Fxg/ml; 
Sigma) in PBS (pH 7.0) for 7 rain at 37 °C. The hybridization mix- 
ture was denatured for 5 rain at 75 °C. For centromere/cosmid dual 
labeling, 10 gl hybridization mixture consisted of 10 ng cosmid 
probe, 10-30 ng centromeric probe as well as 10 ng unlabeled, son- 
icated (200-500 basepairs) human placental DNA (Sigma) in 50% 
formamide, 10% dextran sulfate, and 2X SSC (pH 7). For dual hy- 
bridizations using two centromere probes, the hybridization mixture 
was composed of 10-30 ng centromeric probe and 10 ng unlabeled, 
sonicated (200-500 basepairs), herring sperm DNA (Sigma) in 55 % 
formamide, 10% dextran sulfate, and 2X SSC (pH 7). Hybridization 
was performed overnight at 37 °C. Lymphocyte metaphase spreads 
were used as controls to assure probe specificity. The slides were 
washed and immunostained in five steps as previously described 
[ 19]. If hybridization signals were weak, presumably due to low hy- 
bridization efficiency, hybridization was repeated using the same 
protocol with an increased proteinase K concentration (up to 
10 gg/ml). Proteinase K concentration was reduced if excessive nu- 
clear damage was observed. 
Fig. 1 Dual labeling FISH with probes for centromere 9 (red) and 
centromere 1 (green). Dissociated cell from a formalin-fixed blad- 
der tumor containing four signals for both centromere 9 and centro- 
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Fig. 2 Comparison of percentage of cells with polysomy 17 found 
in two separate hybridizations of 173 tumors. Each circle represents 
one tumor, ra=0.908, n= 173, P<0.0001 
Results 
Flow cytometry 
The mean coeff icient of variation (CV) was 6.2 (range 
2.8-18.1) in all 237 tumors analyzed by FCM. Ploidy was 
determined in the 193 (81%) cases with a diploid CV <8%. 
Fi f ty-two of these tumors were diploid, 21 were peridi-  
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Fig. 3 FISH aberrations in tumors with differing ploidy type. Bars 
indicate the frequency in which polysomies or losses of at least one 
chromosome (X, Y, 1, 7, 9, 17) occurred in tumors with differing 
ploidy types 
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ploid, 25 were tetraploid, 55 were aneuploid, and 40 were 
multiploid. 
F ISH analysis 
F ISH analyses with centromeric probes were successful in 
most cases. The slides were interpretable for centromere 
X in 184 of 191 (96%), for centromere Y in 125 of 133 
(94%), for chromosome 1 in 127 of 135 (95%), for chro- 
mosome 7 in 181 of 199 (91%), for chromosome 9 in 186 
of 215 (87%), and for chromosome 17 in 238 of 280 tu- 
mors (85%). Fifteen tumors were examined for one, 30 for 
two, 47 of three, 39 for four, 66 for five, and 56 for all six 
chromosomes. Most tumors were heterogeneous, contain- 
ing more than one signif icant population with identical 
centromere counts. A cell of a representative case hybri-  
dized with probes for the centromeres 1 and 9 is shown in 
Fig. 1. The fraction of polysomic ells ranged between 0% 
and 100% for all chromosomes. A second hybridizat ion for 
chromosome 17 was performed in 173 tumors. This 
showed that the fraction of polysomic ells was highly re- 
producible (Fig. 2). A po lysomy (>2 centromere signals in 
210% of cells) was found for chromosome X in 58%, for 
chromosome Y in 40%, for chromosome 1 in 76%, for chro- 
mosome 7 in 68%, for chromosome 9 in 52%, and for chro- 
Fig. 4 Polysomies in tumors 
with differing ploidy type. The 
frequency of polysomies of 
chromosomes X, 1, 7, and 17 
are shown as separate bars for 
tumors with differing ploidy 
types 
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Table 1 Predominant popula- 
tions in bladder tumors exam- 
ined by FISH 
FCM: diploid peridiploid tetraploid aneuploid multiploid 
Chromosome Sex N Predominant population (tumors %) 
0 1 2 3 4 >4 
Chromosome Y 
Chromosome X 
Chromosome 1 
Chromosome 7 
Chromosome 9 
Chromosome 17 
M 
F 
125 29 34 34 1 2 0 
131 0 45 51 3 1 0 
53 0 15 26 26 23 10 
127 0 2 27 33 33 5 
181 0 0._55 32.5 22 38 7 
186 0 18 40 19 20 3 
213 0 0.5 40 20.5 34 5 
a Largest aneusomic population having either _>10% polysomic ells or _>20% cells with less than the 
expected number of chromosomes 
b The expected number of chromosomes is printed in bold for each chromosome. Tumors with chromo- 
somal osses are underlined 
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Fig. g Chromosomal losses and ploidy. The frequency of chromo- 
some 9 and Y losses in tumors with different FCM findings is de- 
picted as separate bars 
mosome 17 in 64%. A polysomy of at least one chromo- 
some was seen in 191 of 273 tumors (75.5%) examined by 
FISH. The distribution of the predominant populations for 
all chromosomes in all tumors is shown in Table 1. Fewer 
than the expected number of chromosomes were mostly 
found for chromosome Y (29% of tumors), and chromo- 
some 9 (18% of tumors). Interestingly there was a mono- 
somy X in 15% of the examined female patients while a 
nullisomy X was never observed in male patients. Chro- 
mosomal losses were rare (<2%) for the chromosomes 1,
7, and 17. A chromosome 9 loss according to our defini- 
tion (including monosomy 9 and relative chromosome 9 
losses) was found in 36% of tumors. 
FISH and FCM 
Chromosomal berrations by FISH were found in 107 of 
108 tumors that were tetraploid, aneuploid, or multiploid 
by FCM (Fig. 3). One multiploid tumor with a total of 37% 
aneuploid cells by FCM showed no chromosomal berra- 
tions by FISH. However, only two chromosomes had been 
examined in this case. Numerical aberrations of at least one 
chromosome were also detected in 16 of 21 peridiploid 
(76%), and 29 of 49 diploid tumors (59%). A separate 
analysis of polysomies and chromosomal losses showed 
that polysomies were strongly associated with presence 
of tetraploid/aneuploid/multiploidy populations by FCM 
(P < 0.001; Fig. 4) while there was no significant relation- 
ship between losses of the chromosomes Y and 9 and FCM 
ploidy (Fig. 5). 
DNA aberrations and tumor phenotype 
As a rule the fraction of tumors showing chromosomal b- 
errations increased with the number of FISH probes used 
(Fig. 6). This was prominent when one to four FISH probes 
were applied while there was no further increase in the 
number of polysomies detected when four to six probes 
were employed. Presence of a major DNA aberration by 
FCM (tetraploidy, aneuploidy, or multiploidy) and poly- 
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Fig. 6 Relationship between the frequency of aneusomy detection 
and the number of FISH probes applied. The percentage of tumors 
with detected polysomy or loss of at least one of the chromosomes 
X, Y, 1, 7, 9, and 17 as related to the number of chromosomes ex- 
amined is shown separately for pTa/G 1-2 tumors (/eft) and invasive 
carcinomas (pT1-4). N number of tumors examined, N Chr number 
of chromosomes examined 
grade stage 
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Fig. 7 Relationship of FISH and FCM findings with tumor grade 
and stage. The frequency of detected aberrations i shown as bars 
for each grade and stage. Tumors with less than four chromosomes 
examined by FISH were excluded from this analysis 
somies as detected by FISH were strongly associated with 
a high tumor grade and an invasive tumor stage (pT1-4). 
The fraction of detectable aberrations increased continu- 
ously from grade 1 over grade 2 to grade 3 tumors with 
highly significant differences between grade 1 and grade 2 
tumors (P<0.0001) and between grade 2 and grade 3 tu- 
mors (P<0.0001, Fig. 7). A marked difference was also 
seen between pTa and pT 1 carcinomas (P < 0.0001), while 
there was no significant further increase in the number of 
aberrations from pT1 to pT2-4 carcinomas. In contrast to 
polysomies, losses of the chromosomes Y and 9 were not 
significantly associated with tumor grade and stage (data 
not shown). 
Discussion 
These results show that alterations of the cellular DNA 
content occur frequently in bladder carcinomas. This is 
consistent with a number of previous tudies using image 
cytometry, flow cytometry, or FISH for detection of DNA 
aberrations [1, 8, 9, 18, 23]. Importantly, the differences in
aneuploidy and polysomies of all chromosomes xamined 
were clearly more prominent between pTa and pT1 tumors 
than between pT1 and pT2-4 tumors. The concept that pT1 
tumors are biologically closer to pT2-T4 tumors is also 
supported by marked differences in p53 lesions and other 
cytogenetic alterations between pTa and pT1 carcinomas 
[19, 20]. These results argue against he current concept of 
grouping pTa and pT 1 tumors together as "superficial blad- 
der carcinomas." 
Three of the FISH probes used in this study were se- 
lected because alterations of these chromosomes are 
known to occur frequently in bladder tumors. Chromosome 
9 carries one or several tumor suppressor genes with rele- 
vance for bladder cancer, loss of chromosome Y has been 
suggested to have prognostic significance in bladder tu- 
mors, and for chromosome 7 it was suggested that a tri- 
somy could represent an initial event in bladder carcino- 
genesis [11, 16, 17]. The chromosomes X, 1, and 17 were 
selected because high-quality centromere probes were 
available. 
Our FISH analyses of multiple chromosomes in indi- 
vidual tumors howed that polysomies were usually not re- 
stricted to one chromosome but involved several if not all 
chromosomes xamined. This suggests that most chromo- 
somal aberrations which are detectable by FISH are non- 
specific, being the result of an event involving more or less 
the entire genome. This fits well with models suggesting 
that progression of malignant tumors goes along with se- 
quential changes of their cellular DNA content. It is be- 
lieved that early genomic alteration i cludes losses or gains 
of a few chromosomes orsubchromosomal regions that can 
result in a peridiploid DNA histogram [4]. Development 
of aneuploidy is likely to occur through tetraploidization 
of previously diploid or peridiploid tumors and a subse- 
quent loss of chromosomal material [23]. Our hypothesis 
that most polysomies detected by FISH may be the result 
of a previous tetraploidization is further supported by the 
equally high frequencies of polysomies of all chromo- 
somes examined in tumors with an FCM result consistent 
with a previous tetraptoidization (tetraploid, aneuploid, 
and multiploid tumors) as shown in Fig. 4. 
To evaluate whether numerical aberrations of the chro- 
mosomes examined can be specific events potentially in- 
volved in the initiation of bladder cancer, we screened for 
tumors having only one chromosomal berration. Such tu- 
mors are likely to be diploid by FCM, since the sensitiv- 
ity of FCM is not sufficient o allow detection of gains or 
losses of single chromosomes in formalin-fixed tissues. 
Among 126 tumors which were examined for at least 4 
chromosomes by FISH and also by FCM, there were only 
10 diploid tumors having a numerical alteration of a sin- 
gle chromosome (Table 2). While it cannot be excluded 
that hese ten tumors had aberrations ofother chromosomes 
not examined in this study, this result shows that sole nu- 
merical aberrations of the selected chromosomes are rare 
in bladder cancer. Five different aberrations were found 
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among ten tumors having only one aberration and no sin- 
gle chromosome was solely involved in more than three 
tumors. Therefore, an important role of numerical aberra- 
tion of the examined chromosomes for bladder cancer in- 
itiation seems unlikely. This does not rule out, however, 
that an altered function of genes on these chromosomes - 
for example MTS 1/2 on chromosome 9 - is important for 
bladder cancer development. 
The comparison of FISH and FCM findings revealed a
superior sensitivity of FISH for detection of DNA aberra- 
tions. The finding of chromosomal berrations by FISH in 
all but one of 108 tumors found to be tetraploid, aneuploid, 
or multiploid by FCM is comparable to the results of pre- 
vious studies on prostate, bladder, and ovarian carcinomas, 
where the fraction of FCM aneuploid tumors without de- 
tectable aberrations by FISH was low [7]. The finding of 
chromosomal berrations in 59% of the FCM diploid tu- 
mors is also in agreement with a previous study compair- 
ing FISH and FCM in bladder cancer [7]. Interestingly the 
fraction of tumors with aberrations was only slightly higher 
in peridiploid than in diploid tumors. It is possible that the 
application of additional probes could have resulted in a 
better result in the subset of peridiploid tumors, even 
though the application of more than four probes did not 
further improve the sensitivity of FISH in the entire patient 
set. 
There was no association between chromosome Y and 
9 losses and FCM aneuploidy in this set of patients. This 
observation is consistent with two different ypes of "ge- 
netic instability" in bladder cancer. One type of instability 
obviously allows tetraploidization and development of 
aneuploidy. An inactivation of the p53 tumor suppressor 
gene is likely to be involved in the pathway leading to this 
type of instability since p53 alterations are strongly linked 
to polysomies in bladder cancer [19, 21, 22]. It is estimated 
that mutations or deletions of p53 occur in more than 50% 
of invasive bladder tumors [2, 3, 13, 15, 27]. The conspic- 
uous lack of an association between chromosomal losses 
and FCM aneuploidy raises the possibility that the devel- 
opment of minor chromosomal berrations including chro- 
mosome Y or 9 losses is facilitated by a different ype of 
"genetic instability." Such a second mechanism could be 
independent of p53 alterations since losses of the chromo- 
somes Y and 9 were not related to p53 immunostaining in 
previous studies [21, 22]. 
A major problem in the management of bladder cancer 
patients is the diagnosis of recurrent bladder tumors. Al- 
though urinary cells are readily accessible for cytological 
examination, the sensitivity (and specificity) of cytology 
alone is poor in low-grade tumors [12]. Previous studies 
have suggested that DNA measurement of urinary cells by 
FCM or image cytometry could be a valuable tool for the 
diagnosis of bladder cancer ecurrences (reviewed in [26]). 
The results of this study indicate that the sensitivity of 
FISH for detection of aberrant urinary cells could be even 
higher than the sensitivity of FCM. Importantly the sensi- 
tivity of FISH is particularly high in grade 1 tumors, where 
the sensitivity of urinary cytology ranges between 16% and 
30%. In this study DNA aberrations were detected by FCM 
in 26% and by FISH in 68% of grade 1 tumors. Consider- 
ing that not all FISH probes applied in this study were se- 
lected for chromosomes or loci known to be frequently 
affected in low-grade bladder tumors, it appears likely that 
FISH detection of aberrant urinary cells could be further 
improved by an optimized set of probes. If  so, FISH could 
be a powerful tool for urinary tract cytology, even though 
its specificity will not reach 100% because of rare chro- 
mosomal aberrations in normal urothelium [22]. 
In summary, these data show that an aberrant DNA con- 
tent is frequent in bladder carcinomas. The striking differ- 
ence in DNA aberrations between pTa and pT1 tumors 
challenges the concept of grouping these tumors together 
as "superficial bladder carcinomas." The high sensitivity 
ofFISH for detection of DNA alterations in grade 1 tumors 
suggests that the cytological diagnosis of bladder cancer 
recurrences could be substantially improved by FISH. This 
is especially true because FISH is a simple method requir- 
ing very little material with the potential for routine appli- 
cation. 
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